Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:ITCI NASDAQ:NAMS NASDAQ:ROIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$202.00+0.5%$199.92$118.03▼$216.45$12.46B0.41472,097 shs369,067 shsITCIIntra-Cellular Therapies$131.87$131.87$70.90▼$131.98$14.05B0.691.57 million shsN/ANAMSNewAmsterdam Pharma$35.72-1.5%$28.94$14.06▼$41.47$4.02B0.021.40 million shs746,397 shsROIVRoivant Sciences$18.22+0.6%$14.60$8.73▼$18.42$12.44B1.27.64 million shs6.95 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S0.00%-4.04%+6.46%+20.62%+58.20%ITCIIntra-Cellular Therapies0.00%0.00%0.00%0.00%+75.78%NAMSNewAmsterdam Pharma0.00%-1.87%+35.87%+51.36%+85.08%ROIVRoivant Sciences0.00%+5.56%+21.79%+57.75%+56.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$202.00+0.5%$199.92$118.03▼$216.45$12.46B0.41472,097 shs369,067 shsITCIIntra-Cellular Therapies$131.87$131.87$70.90▼$131.98$14.05B0.691.57 million shsN/ANAMSNewAmsterdam Pharma$35.72-1.5%$28.94$14.06▼$41.47$4.02B0.021.40 million shs746,397 shsROIVRoivant Sciences$18.22+0.6%$14.60$8.73▼$18.42$12.44B1.27.64 million shs6.95 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S0.00%-4.04%+6.46%+20.62%+58.20%ITCIIntra-Cellular Therapies0.00%0.00%0.00%0.00%+75.78%NAMSNewAmsterdam Pharma0.00%-1.87%+35.87%+51.36%+85.08%ROIVRoivant Sciences0.00%+5.56%+21.79%+57.75%+56.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 2.94Moderate Buy$249.8023.66% UpsideITCIIntra-Cellular Therapies 2.11Hold$121.29-8.03% DownsideNAMSNewAmsterdam Pharma 2.70Moderate Buy$43.2020.94% UpsideROIVRoivant Sciences 2.90Moderate Buy$19.949.43% UpsideCurrent Analyst Ratings BreakdownLatest NAMS, ITCI, ROIV, and ASND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025NAMSNewAmsterdam PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/25/2025ROIVRoivant SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)10/24/2025ASNDAscendis Pharma A/SWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/20/2025NAMSNewAmsterdam PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$52.0010/20/2025NAMSNewAmsterdam PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$52.0010/17/2025NAMSNewAmsterdam PharmaCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$42.00 ➝ $50.0010/17/2025ASNDAscendis Pharma A/SRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$271.0010/16/2025ASNDAscendis Pharma A/SRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/13/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$203.00 ➝ $254.0010/9/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$260.00 ➝ $264.0010/8/2025ASNDAscendis Pharma A/SWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$393.54M31.66N/AN/A($1.88) per share-107.45ITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44NAMSNewAmsterdam Pharma$45.56M88.30N/AN/A$8.20 per share4.36ROIVRoivant Sciences$29.05M428.30N/AN/A$7.45 per share2.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$5.16N/A841.67N/A-54.94%N/A-24.31%11/13/2025 (Estimated)ITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/ANAMSNewAmsterdam Pharma-$241.60M-$1.62N/AN/AN/A-259.07%-27.27%-25.00%11/5/2025 (Estimated)ROIVRoivant Sciences-$171.98M-$0.70N/AN/AN/A-2,111.79%-15.90%-14.95%11/11/2025 (Estimated)Latest NAMS, ITCI, ROIV, and ASND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025ASNDAscendis Pharma A/S-$0.49N/AN/AN/AN/AN/A11/11/2025Q2 2026ROIVRoivant Sciences-$0.27N/AN/AN/A$6.92 millionN/A11/5/2025Q3 2025NAMSNewAmsterdam Pharma-$0.41N/AN/AN/A$4.54 millionN/A8/7/2025Q2 2025ASNDAscendis Pharma A/S-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 million8/6/2025Q2 2025NAMSNewAmsterdam Pharma-$0.52-$0.15+$0.37-$0.15$1.44 million$19.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/AITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.020.69ITCIIntra-Cellular TherapiesN/A7.667.51NAMSNewAmsterdam PharmaN/A21.0821.08ROIVRoivant SciencesN/A40.5440.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/AITCIIntra-Cellular Therapies92.33%NAMSNewAmsterdam Pharma89.89%ROIVRoivant Sciences64.76%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%ITCIIntra-Cellular Therapies2.60%NAMSNewAmsterdam Pharma20.84%ROIVRoivant Sciences10.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,01761.69 million37.02 millionOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableNAMSNewAmsterdam Pharma4112.63 million89.16 millionOptionableROIVRoivant Sciences860682.88 million609.13 millionOptionableNAMS, ITCI, ROIV, and ASND HeadlinesRecent News About These CompaniesVIRGINIA RETIREMENT SYSTEMS ET Al Makes New Investment in Roivant Sciences Ltd. $ROIVOctober 24 at 4:42 AM | marketbeat.comPriovant announces positive Phase 3 results for targeted dermatomyositis treatmentOctober 24 at 3:24 AM | ncbiotech.orgNBTS Asset Management Inc. Makes New $348,000 Investment in Roivant Sciences Ltd. $ROIVOctober 22, 2025 | marketbeat.com162,400 Shares in Roivant Sciences Ltd. $ROIV Purchased by TD Asset Management IncOctober 22, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Recommendation of "Moderate Buy" from AnalystsOctober 22, 2025 | americanbankingnews.comRoivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Rating of "Moderate Buy" by AnalystsOctober 22, 2025 | marketbeat.comWall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV)October 21, 2025 | insidermonkey.comRoivant Sciences (NASDAQ:ROIV) Hits New 12-Month High - What's Next?October 21, 2025 | marketbeat.comInsider Selling: Roivant Sciences (NASDAQ:ROIV) CEO Sells 118,418 Shares of StockOctober 18, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 318,282 SharesOctober 18, 2025 | marketbeat.comEric Venker Sells 414,683 Shares of Roivant Sciences (NASDAQ:ROIV) StockOctober 18, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 118,418 SharesOctober 18, 2025 | insidertrades.comEric Venker Sells 20,727 Shares of Roivant Sciences (NASDAQ:ROIV) StockOctober 15, 2025 | marketbeat.comEric Venker Sells 104,940 Shares of Roivant Sciences (NASDAQ:ROIV) StockOctober 15, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Reaches New 12-Month High - Still a Buy?October 15, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) CEO Sells $336,813.75 in StockOctober 15, 2025 | insidertrades.comGoldman Sachs Sticks to Their Buy Rating for Roivant Sciences (ROIV)October 10, 2025 | theglobeandmail.comEric Venker Sells 138,602 Shares of Roivant Sciences (NASDAQ:ROIV) StockOctober 9, 2025 | marketbeat.comEric Venker Sells 171,396 Shares of Roivant Sciences (NASDAQ:ROIV) StockOctober 9, 2025 | marketbeat.comEric Venker Sells 355,161 Shares of Roivant Sciences (NASDAQ:ROIV) StockOctober 9, 2025 | marketbeat.comEric Venker Sells 138,602 Shares of Roivant Sciences (NASDAQ:ROIV) StockOctober 9, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNAMS, ITCI, ROIV, and ASND Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$202.00 +0.99 (+0.49%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$202.50 +0.50 (+0.25%) As of 10/24/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Intra-Cellular Therapies NASDAQ:ITCIIntra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.NewAmsterdam Pharma NASDAQ:NAMS$35.72 -0.56 (-1.54%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$35.96 +0.23 (+0.66%) As of 10/24/2025 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Roivant Sciences NASDAQ:ROIV$18.22 +0.10 (+0.55%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$18.22 0.00 (0.00%) As of 10/24/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
